Implantable access system for prolonged intrapleural immunotherapy

We describe our experience using an implantable Port-A-Cath access system for intrapleural administration of gamma-interferon (gamma-IFN) in malignant mesothelioma patients. Twenty nine patients, with histologically proven malignant mesotheliomas were included in this study. To avoid complications the device was implanted in a subcutaneous pocket, and the catheter was connected via a tunnel. Also, a suction drain was installed in the pocket after placement. This procedure greatly reduced the high infection rate (64%) encountered with conventional open chest tubes. Patients' tolerance was excellent and maintenance minimal. In our opinion, the Port-A-Cath system is the most suitable device for intra-cavitary long-term therapy of malignant pleural effusions.

This article has been cited by other articles:

				T. Shoji, F. Tanaka, K. Yanagihara, K. Inui, and H. Wada Phase II Study of Repeated Intrapleural Chemotherapy Using Implantable Access System for Management of Malignant Pleural Effusion Chest, March 1, 2002; 121(3): 821 - 824. [Abstract] [Full Text] [PDF]

				F. Krug, D. Psathakis, U. Hirsch, and H.-P. Bruch The K-port concept: Proposal for optimising a fully implantable port system Journal of Oncology Pharmacy Practice, June 1, 1999; 5(2): 67 - 74. [Abstract] [PDF]